Search
Tioconazole
go.drugbank.com/drugs/DB01007ApprovedTioconazole interacts with 14-alpha demethylase, a cytochrome P-450 enzyme that converts lanosterol to ergosterol, an essential component of the yeast membrane.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP2C19 InhibitorsMycophenolic acid
go.drugbank.com/drugs/DB01024ApprovedInvestigationalMycophenolic acid is a potent immunosuppressant agent that inhibits de novo purine biosynthesis. It was derived from Penicillium stoloniferum, and has also shown antibacterial, antifungal and antiviral properties. . Mycophenolic acid is ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 SubstratesGatifloxacin
go.drugbank.com/drugs/DB01044ApprovedInvestigationalWithdrawnGatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under...
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP1A2 InhibitorsRifampin
go.drugbank.com/drugs/DB01045ApprovedInvestigationalRifampin, also known as rifampicin, is a broad-spectrum antimicrobial that was first discovered in 1965 and clinically used in 1968. Rifampin is used to treat tuberculosis and works by inhibiting the microbial DNA-dependent RNA polymeras...
Categories: P-glycoprotein inducers, Cytochrome P-450 CYP1A2 InducersPromethazine
go.drugbank.com/drugs/DB01069ApprovedInvestigationalPromethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of phenothiazine that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indicatio...
Categories: Dopamine D2 Receptor Antagonists, P-glycoprotein inhibitorsTegaserod
go.drugbank.com/drugs/DB01079ApprovedWithdrawnNovartis' brand name Zelnorm (tegaserod) had originally received approval from the US FDA in 2002 for the treatment of irritable bowel syndrome with constipation (IBS-C). It was, however, voluntarily withdrawn from widespread use in the ...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesCefadroxil
go.drugbank.com/drugs/DB01140ApprovedInvestigationalVet approvedWithdrawnLong-acting, broad-spectrum, water-soluble, cephalexin derivative.
Cefprozil
go.drugbank.com/drugs/DB01150ApprovedInvestigationalCefprozil is a cephalosporin antibiotic that is commonly employed to treat a variety of bacterial infections, including those of the ear and skin, bronchitis, and others.
Gemifloxacin
go.drugbank.com/drugs/DB01155ApprovedInvestigationalGemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemi...
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme InhibitorsBupropion
go.drugbank.com/drugs/DB01156ApprovedInvestigational[L6562] Studies have shown that the combined activity of bupropion and [naltrexone] increase the firing rate of hypothalamic pro-opiomelanocortin (POMC) neurons and blockade of opioid receptor-mediated … anti-withdrawal effects by inhibiting dopamine reuptake, which is thought to be involved in the reward pathways associated with nicotine, and through the antagonism of the nicotinic acetylcholinergic receptor
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 Substrates